-
1
-
-
0028588691
-
Relationship between obesity and concordance rate for type 2 (non-insulin-dependent) diabetes mellitus among twins
-
Matsuda A, Kuzuya T. Relationship between obesity and concordance rate for type 2 (non-insulin-dependent) diabetes mellitus among twins. Diabetes Res Clin Pract 1994; 26: 137-43.
-
(1994)
Diabetes Res Clin Pract
, vol.26
, pp. 137-43
-
-
Matsuda, A.1
Kuzuya, T.2
-
2
-
-
0033624575
-
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
-
Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80.
-
(2000)
Nat Genet
, vol.26
, pp. 76-80
-
-
Altshuler, D.1
Hirschhorn, J.N.2
Klannemark, M.3
Lindgren, C.M.4
Vohl, M.C.5
Nemesh, J.6
-
3
-
-
0025132245
-
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
-
Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-50.
-
(1990)
Nature
, vol.347
, pp. 645-50
-
-
Issemann, I.1
Green, S.2
-
4
-
-
0032588487
-
PPARgamma, the ultimate thrifty gene
-
Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 1999; 42: 1033-49.
-
(1999)
Diabetologia
, vol.42
, pp. 1033-49
-
-
Auwerx, J.1
-
5
-
-
0031595923
-
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
-
Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-7.
-
(1998)
Nat Genet
, vol.20
, pp. 284-7
-
-
Deeb, S.S.1
Fajas, L.2
Nemoto, M.3
Pihlajamaki, J.4
Mykkanen, L.5
Kuusisto, J.6
-
6
-
-
0345363159
-
Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects
-
Hamann A, Munzberg H, Buttron P, Busing B, Hinney A, Mayer H, et al. Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects. Eur J Endocrinol 1999; 141: 90-2.
-
(1999)
Eur J Endocrinol
, vol.141
, pp. 90-2
-
-
Hamann, A.1
Munzberg, H.2
Buttron, P.3
Busing, B.4
Hinney, A.5
Mayer, H.6
-
7
-
-
0345164399
-
Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: Identification of a Pro12Ala PPAR gamma 2 missense mutation
-
Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997; 241: 270-4.
-
(1997)
Biochem Biophys Res Commun
, vol.241
, pp. 270-4
-
-
Yen, C.J.1
Beamer, B.A.2
Negri, C.3
Silver, K.4
Brown, K.A.5
Yarnall, D.P.6
-
8
-
-
23444457610
-
Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes
-
Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS, et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005; 78: 202-8.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 202-8
-
-
Kang, E.S.1
Park, S.Y.2
Kim, H.J.3
Kim, C.S.4
Ahn, C.W.5
Cha, B.S.6
-
9
-
-
77649214654
-
A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese
-
Tsai FJ, Yang CF, Chen CC, Chuang LM, Lu CH, Chang CT, et al. A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet 2010; 6: e1000847.
-
(2010)
PLoS Genet
, vol.6
-
-
Tsai, F.J.1
Yang, C.F.2
Chen, C.C.3
Chuang, L.M.4
Lu, C.H.5
Chang, C.T.6
-
10
-
-
33750299450
-
Protein tyrosine phosphatases: From genes, to function, to disease
-
Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006; 7: 833-46.
-
(2006)
Nat Rev Mol Cell Biol
, vol.7
, pp. 833-46
-
-
Tonks, N.K.1
-
11
-
-
16844386333
-
Functional significance of the LAR receptor protein tyrosine phosphatase family in development and diseases
-
Chagnon MJ, Uetani N, Tremblay ML. Functional significance of the LAR receptor protein tyrosine phosphatase family in development and diseases. Biochem Cell Biol 2004; 82: 664-75.
-
(2004)
Biochem Cell Biol
, vol.82
, pp. 664-75
-
-
Chagnon, M.J.1
Uetani, N.2
Tremblay, M.L.3
-
12
-
-
34347228957
-
Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen
-
Kawase T, Akatsuka Y, Torikai H, Morishima S, Oka A, Tsujimura A, et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 2007; 110: 1055-63.
-
(2007)
Blood
, vol.110
, pp. 1055-63
-
-
Kawase, T.1
Akatsuka, Y.2
Torikai, H.3
Morishima, S.4
Oka, A.5
Tsujimura, A.6
-
13
-
-
33749005081
-
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988GA: Evidence for modulation of splicing events
-
Toscano C, Klein K, Blievernicht J, Schaeffeler E, Saussele T, Raimundo S, et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988GA: evidence for modulation of splicing events. Pharmacogenet Genomics 2006; 16: 755-66.
-
(2006)
Pharmacogenet Genomics
, vol.16
, pp. 755-66
-
-
Toscano, C.1
Klein, K.2
Blievernicht, J.3
Schaeffeler, E.4
Saussele, T.5
Raimundo, S.6
-
14
-
-
18144431682
-
The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes
-
Kang ES, Park SY, Kim HJ, Ahn CW, Nam M, Cha BS, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005; 28: 1139-44.
-
(2005)
Diabetes Care
, vol.28
, pp. 1139-44
-
-
Kang, E.S.1
Park, S.Y.2
Kim, H.J.3
Ahn, C.W.4
Nam, M.5
Cha, B.S.6
-
15
-
-
0034923501
-
Peroxisome proliferatoractivated receptor gamma and metabolic disease
-
Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferatoractivated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341-67.
-
(2001)
Annu Rev Biochem
, vol.70
, pp. 341-67
-
-
Willson, T.M.1
Lambert, M.H.2
Kliewer, S.A.3
-
16
-
-
0036872996
-
Addressing the insulin resistance syndrome: A role for the thiazolidinediones
-
Zimmet P. Addressing the insulin resistance syndrome: a role for the thiazolidinediones. Trends Cardiovasc Med 2002; 12: 354-62.
-
(2002)
Trends Cardiovasc Med
, vol.12
, pp. 354-62
-
-
Zimmet, P.1
-
18
-
-
0036072223
-
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients
-
Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-91.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 2784-91
-
-
Miyazaki, Y.1
Mahankali, A.2
Matsuda, M.3
Mahankali, S.4
Hardies, J.5
Cusi, K.6
-
19
-
-
0036203666
-
Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records
-
Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-96.
-
(2002)
Clin Ther
, vol.24
, pp. 378-96
-
-
Boyle, P.J.1
King, A.B.2
Olansky, L.3
Marchetti, A.4
Lau, H.5
Magar, R.6
-
20
-
-
0033754530
-
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study the Pioglitazone 001 Study Group
-
Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-11.
-
(2000)
Diabetes Care
, vol.23
, pp. 1605-11
-
-
Aronoff, S.1
Rosenblatt, S.2
Braithwaite, S.3
Egan, J.W.4
Mathisen, A.L.5
Schneider, R.L.6
-
21
-
-
0038746876
-
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus
-
Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 1074-95.
-
(2003)
Clin Ther
, vol.25
, pp. 1074-95
-
-
Herz, M.1
Johns, D.2
Reviriego, J.3
Grossman, L.D.4
Godin, C.5
Duran, S.6
-
23
-
-
18744401592
-
Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: A doubleblind, placebo-controlled study
-
Scherbaum WA, Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a doubleblind, placebo-controlled study. Horm Metab Res 2002; 34: 589-95.
-
(2002)
Horm Metab Res
, vol.34
, pp. 589-95
-
-
Scherbaum, W.A.1
Goke, B.2
-
24
-
-
78649328506
-
Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients
-
Huang Q, Yin JY, Dai XP, Wu J, Chen X, Deng CS, et al. Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. Eur J Clin Pharmacol 2010; 66: 1207-15.
-
(2010)
Eur J Clin Pharmacol
, vol.66
, pp. 1207-15
-
-
Huang, Q.1
Yin, J.Y.2
Dai, X.P.3
Wu, J.4
Chen, X.5
Deng, C.S.6
-
25
-
-
0029016829
-
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
-
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6.
-
(1995)
J Biol Chem
, vol.270
, pp. 12953-6
-
-
Lehmann, J.M.1
Moore, L.B.2
Smith-Oliver, T.A.3
Wilkison, W.O.4
Willson, T.M.5
Kliewer, S.A.6
-
26
-
-
0034607051
-
Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis
-
Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000; 268: 178-82.
-
(2000)
Biochem Biophys Res Commun
, vol.268
, pp. 178-82
-
-
Masugi, J.1
Tamori, Y.2
Mori, H.3
Koike, T.4
Kasuga, M.5
-
27
-
-
77955481012
-
Common polymorphisms of the peroxisome proliferator-activated receptorgamma (Pro12Ala) and peroxisome proliferator-activated receptorgamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus
-
Hsieh MC, Lin KD, Tien KJ, Tu ST, Hsiao JY, Chang SJ, et al. Common polymorphisms of the peroxisome proliferator-activated receptorgamma (Pro12Ala) and peroxisome proliferator-activated receptorgamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism 2010; 59: 1139-44.
-
(2010)
Metabolism
, vol.59
, pp. 1139-44
-
-
Hsieh, M.C.1
Lin, K.D.2
Tien, K.J.3
Tu, S.T.4
Hsiao, J.Y.5
Chang, S.J.6
-
28
-
-
80455160172
-
Polymorphism of peroxisome proliferator-activated receptor gamma (PPARgamma) Pro12Ala in the Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes
-
Namvaran F, Azarpira N, Rahimi-Moghaddam P, Dabbaghmanesh MH. Polymorphism of peroxisome proliferator-activated receptor gamma (PPARgamma) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. Eur J Pharmacol 2011; 671: 1-6.
-
(2011)
Eur J Pharmacol
, vol.671
, pp. 1-6
-
-
Namvaran, F.1
Azarpira, N.2
Rahimi-Moghaddam, P.3
Dabbaghmanesh, M.H.4
-
29
-
-
18344417084
-
Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes
-
Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003; 26: 825-31.
-
(2003)
Diabetes Care
, vol.26
, pp. 825-31
-
-
Bluher, M.1
Lubben, G.2
Paschke, R.3
-
30
-
-
34250631631
-
Heterogeneous effect of peroxisome proliferatoractivated receptor gamma2 Ala 12 variant on type 2 diabetes risk
-
Ludovico O, Pellegrini F, Di Paola R, Minenna A, Mastroianno S, Cardellini M, et al. Heterogeneous effect of peroxisome proliferatoractivated receptor gamma2 Ala12 variant on type 2 diabetes risk. Obesity (Silver Spring) 2007; 15: 1076-81.
-
(2007)
Obesity (Silver Spring)
, vol.15
, pp. 1076-81
-
-
Ludovico, O.1
Pellegrini, F.2
Di Paola, R.3
Minenna, A.4
Mastroianno, S.5
Cardellini, M.6
-
31
-
-
0029417204
-
The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: Multiple human LAR PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LARinteracting protein LIP.1
-
Pulido R, Serra-Pages C, Tang M, Streuli M. The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LARinteracting protein LIP.1. Proc Natl Acad Sci USA 1995; 92: 11686-90.
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 11686-90
-
-
Pulido, R.1
Serra-Pages, C.2
Tang, M.3
Streuli, M.4
-
32
-
-
0035491792
-
Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptorgamma-mediated changes in gene expression
-
Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhausl W, et al. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptorgamma-mediated changes in gene expression. Diabetes 2001; 50: 2309-15.
-
(2001)
Diabetes
, vol.50
, pp. 2309-15
-
-
Brunmair, B.1
Gras, F.2
Neschen, S.3
Roden, M.4
Wagner, L.5
Waldhausl, W.6
-
33
-
-
77958039797
-
Novel thiazolidinedione derivatives with anti-obesity effects: Dual action as PTP1B inhibitors and PPAR-gamma activators
-
Bhattarai BR, Kafle B, Hwang JS, Ham SW, Lee KH, Park H, et al. Novel thiazolidinedione derivatives with anti-obesity effects: dual action as PTP1B inhibitors and PPAR-gamma activators. Bioorg Med Chem Lett 2010; 20: 6758-63.
-
(2010)
Bioorg Med Chem Lett
, vol.20
, pp. 6758-63
-
-
Bhattarai, B.R.1
Kafle, B.2
Hwang, J.S.3
Ham, S.W.4
Lee, K.H.5
Park, H.6
-
34
-
-
30544435421
-
Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocintreated diabetic rats
-
Wu Y, Ouyang JP, Wu K, Wang SS, Wen CY, Xia ZY. Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocintreated diabetic rats. Br J Pharmacol 2005; 146: 234-43.
-
(2005)
Br J Pharmacol
, vol.146
, pp. 234-43
-
-
Wu, Y.1
Ouyang, J.P.2
Wu, K.3
Wang, S.S.4
Wen, C.Y.5
Xia, Z.Y.6
-
35
-
-
70649100416
-
Cytochrome P450 2C8 pharmacogenetics: A review of clinical studies
-
Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 2009; 10: 1489-510.
-
(2009)
Pharmacogenomics
, vol.10
, pp. 1489-510
-
-
Daily, E.B.1
Aquilante, C.L.2
-
36
-
-
33745703773
-
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: Potential for interactions with CYP2C8 inhibitors
-
Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006; 99: 44-51.
-
(2006)
Basic Clin Pharmacol Toxicol
, vol.99
, pp. 44-51
-
-
Jaakkola, T.1
Laitila, J.2
Neuvonen, P.J.3
Backman, J.T.4
|